Research ExplorerPublicationsBiomarker in der Primärprävention

Biomarker in der Primärprävention

Standard

Biomarker in der Primärprävention : Aussagekräftige Diagnose anhand von Biomarkerwerten? / Schulte, Christian; Zeller, Tanja.

In: HERZ, Vol. 45, No. 1, 02.2020, p. 10-16.

Research output: SCORING: Contribution to journal › SCORING: Review article › Research

Harvard

Schulte, C & Zeller, T 2020, 'Biomarker in der Primärprävention: Aussagekräftige Diagnose anhand von Biomarkerwerten?', HERZ, vol. 45, no. 1, pp. 10-16. https://doi.org/10.1007/s00059-019-04874-2

APA

Schulte, C., & Zeller, T. (2020). Biomarker in der Primärprävention: Aussagekräftige Diagnose anhand von Biomarkerwerten? HERZ, 45(1), 10-16. https://doi.org/10.1007/s00059-019-04874-2

Vancouver

Schulte C, Zeller T. Biomarker in der Primärprävention: Aussagekräftige Diagnose anhand von Biomarkerwerten? HERZ. 2020 Feb;45(1):10-16. https://doi.org/10.1007/s00059-019-04874-2

Bibtex

@article{d304d06bafa24326b6b1182032645fc9,
title = "Biomarker in der Prim{\"a}rpr{\"a}vention: Aussagekr{\"a}ftige Diagnose anhand von Biomarkerwerten?",
abstract = "Cardiovascular (CV) risk assessment is based on the utilization of risk scores, enabling clinicians to estimate an individual's risk to develop CV pathologies and events. Such risk scores comprise classic CV risk factors such as smoking, diabetes, hypertension, and blood cholesterol levels. Recently, other CV biomarkers such as cardiac troponins have been suggested and evaluated as alternative biomarkers not only in the acute diagnostic setting of myocardial infarction, but also as markers for risk stratification in the general population. In this review, we summarize the current knowledge on biomarkers in the field of primary prevention in cardiovascular disease (CVD). Furthermore, we present potential alternative biomarker-based strategies for CV risk assessment. In this respect we provide an outlook on the potential use of genomic variation as well as circulating non-coding RNAs to complement current risk assessment strategies so as to further personalize risk stratification in CVD.",
keywords = "Biomarkers/analysis, Cardiovascular Diseases/diagnosis, Humans, Hypertension/diagnosis, Myocardial Infarction/diagnosis, Primary Prevention, Risk Assessment, Risk Factors",
author = "Christian Schulte and Tanja Zeller",
year = "2020",
month = feb,
doi = "10.1007/s00059-019-04874-2",
language = "Deutsch",
volume = "45",
pages = "10--16",
journal = "HERZ",
issn = "0340-9937",
publisher = "Urban und Vogel",
number = "1",

}

RIS

TY - JOUR

T1 - Biomarker in der Primärprävention

T2 - Aussagekräftige Diagnose anhand von Biomarkerwerten?

AU - Schulte, Christian

AU - Zeller, Tanja

PY - 2020/2

Y1 - 2020/2

N2 - Cardiovascular (CV) risk assessment is based on the utilization of risk scores, enabling clinicians to estimate an individual's risk to develop CV pathologies and events. Such risk scores comprise classic CV risk factors such as smoking, diabetes, hypertension, and blood cholesterol levels. Recently, other CV biomarkers such as cardiac troponins have been suggested and evaluated as alternative biomarkers not only in the acute diagnostic setting of myocardial infarction, but also as markers for risk stratification in the general population. In this review, we summarize the current knowledge on biomarkers in the field of primary prevention in cardiovascular disease (CVD). Furthermore, we present potential alternative biomarker-based strategies for CV risk assessment. In this respect we provide an outlook on the potential use of genomic variation as well as circulating non-coding RNAs to complement current risk assessment strategies so as to further personalize risk stratification in CVD.

AB - Cardiovascular (CV) risk assessment is based on the utilization of risk scores, enabling clinicians to estimate an individual's risk to develop CV pathologies and events. Such risk scores comprise classic CV risk factors such as smoking, diabetes, hypertension, and blood cholesterol levels. Recently, other CV biomarkers such as cardiac troponins have been suggested and evaluated as alternative biomarkers not only in the acute diagnostic setting of myocardial infarction, but also as markers for risk stratification in the general population. In this review, we summarize the current knowledge on biomarkers in the field of primary prevention in cardiovascular disease (CVD). Furthermore, we present potential alternative biomarker-based strategies for CV risk assessment. In this respect we provide an outlook on the potential use of genomic variation as well as circulating non-coding RNAs to complement current risk assessment strategies so as to further personalize risk stratification in CVD.

KW - Biomarkers/analysis

KW - Cardiovascular Diseases/diagnosis

KW - Humans

KW - Hypertension/diagnosis

KW - Myocardial Infarction/diagnosis

KW - Primary Prevention

KW - Risk Assessment

KW - Risk Factors

U2 - 10.1007/s00059-019-04874-2

DO - 10.1007/s00059-019-04874-2

M3 - SCORING: Review

C2 - 31807790

VL - 45

SP - 10

EP - 16

JO - HERZ

JF - HERZ

SN - 0340-9937

IS - 1

ER -